Prescribing information for the Exubera system recommends all patients have baseline spirometry testing, a follow-up 6 months after initiation of
treatment, and yearly follow-up thereafter. Exubera is not recommended for patients with baseline FEV1 or DLCO <70% predicted. In patients who experience a >20% decrease in FEV1, tests should be repeated. If this finding is confirmed, then treatment should be discontinued. Treatment should also be stopped in the rare case of acute bronchospasm (22).
Continue reading here: Insulin Antibodies
Was this article helpful?